Tuesday 13 October 2026
Export PRTA’s income statement to Excel — free account
Prothena Corporation plc
PRTA Healthcare Biotechnology
Prothena Corporation plc’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 77.2%, EPS grew 84.6% and free cash flow grew 44.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.42
0.01
−0.12%
Follow PRTA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 3 | 2 | 7 | 3 | 3 | 4 | 5 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 35.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
53.08 | 5.51 | 22.45 | 47.01 | 10.89 | 561.99 | 775.59 | 426.66 | 51.72 | 1,621.17 |
Altman Z-Score |
(0.24) | 4.88 | 6.85 | 11.61 | 9.31 | (1.49) | 0.70 | (0.33) | 8.22 | 9.61 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 23.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(5.98) | 5.27 | 3.42 | 5.84 | 6.31 | (3.26) | 1.00 | 1.36 | 4.93 | 4.67 |
P/Operating CF |
(22.05) | (15.59) | (40.18) | (509.29) | (97.29) | (25.11) | (43.58) | (19.17) | (36.01) | (50.59) |
Beneish M-Score |
— | — | — | — | — | (3.87) | 33.47 | (9.25) | 19.06 | (3.14) |
P/B ratio |
1.83 | 1.53 | 3.65 | 4.07 | 4.69 | 2.61 | 2.31 | 1.26 | 3.50 | 4.68 |
Price to Tangible BV |
1.83 | 1.53 | 3.65 | 4.07 | 4.69 | 2.61 | 2.31 | 1.26 | 3.50 | 4.68 |
EV/Sales |
21.33 | 2.02 | 15.66 | 33.83 | 8.01 | 214.12 | 314.02 | (21.15) | 36.55 | 1,254.42 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 20.38 | 0.00 | 0.00 | 0.13 | 0.00 | 0.00 |
EV/Operating CF |
(1.26) | (1.82) | (10.68) | (16.76) | 17.34 | (2.27) | (4.83) | 0.71 | (7.67) | (11.38) |
EV/FCF |
(1.26) | (1.82) | (10.47) | (16.69) | 17.45 | (2.27) | (4.78) | 0.67 | (7.47) | (9.96) |
Quick Ratio |
7.53 | 9.72 | 10.99 | 14.17 | 17.31 | 11.48 | 21.21 | 28.65 | 11.18 | 9.42 |
Current Ratio |
7.72 | 10.01 | 11.24 | 14.34 | 17.48 | 11.58 | 21.36 | 28.90 | 11.41 | 9.53 |
Net Debt/EBITDA |
1.46 | 3.12 | 3.40 | 5.69 | (7.35) | 2.81 | 4.76 | 2.75 | 2.74 | 2.46 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.22 | 0.13 | 0.08 | 0.43 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 |
Operating CF/Net income |
0.67 | 1.23 | 0.91 | 0.93 | 1.38 | 0.72 | 0.68 | 0.18 | 0.86 | 0.73 |
Capex/Depreciation |
(0.04) | (0.08) | (0.33) | (0.07) | (0.08) | (0.03) | (0.08) | (0.54) | (1.15) | (6.86) |
| (63.62%) | (23.34%) | (24.85%) | (21.50%) | 20.61% | (48.65%) | (26.07%) | (42.63%) | (39.67%) | (44.10%) | |
| (55.86%) | (19.67%) | (20.22%) | (17.11%) | 14.21% | (29.55%) | (16.92%) | (31.28%) | (32.05%) | (37.89%) | |
ROIC |
0.00% | (621.71%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(88.28%) | (27.80%) | (25.08%) | (17.44%) | 12.10% | (40.27%) | (21.31%) | (33.17%) | (34.52%) | (39.36%) |
Average Days of Receivables |
0.00 | 0.00 | 20.61 | 0.00 | 0.00 | 6.42 | 30.49 | 0.76 | 3.18 | 61.58 |
Research and Development Expense of Revenue |
1,392.52% | 164.64% | 241.40% | 251.48% | 41.02% | 8,778.90% | 6,245.21% | 10,595.08% | 488.92% | 11,330.24% |
Selling, General and Administrative Expense of Revenue |
613.30% | 49.72% | 67.68% | 92.57% | 23.09% | 4,537.28% | 4,390.17% | 4,448.38% | 175.25% | 3,891.56% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
388.68% | 34.01% | 44.78% | 58.11% | 12.29% | 2,580.77% | 2,897.42% | 2,729.01% | 97.26% | 2,362.94% |
Graham Net Nets |
0.52 | 0.57 | 0.25 | 0.23 | 0.20 | 0.31 | 0.37 | 0.63 | 0.24 | 0.17 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 18.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(47.54%) | (16.46%) | (7.19%) | (4.67%) | 2.81% | (23.23%) | (12.32%) | (38.25%) | (10.74%) | (9.36%) |
Free Cash Flow Yield |
(31.85%) | (20.19%) | (6.66%) | (4.31%) | 4.21% | (16.80%) | (8.48%) | (7.36%) | (9.46%) | (7.77%) |
Revenue per Share |
0.18 | 2.51 | 1.72 | 1.14 | 4.54 | 0.02 | 0.02 | 0.02 | 0.73 | 0.03 |
Operating CF per Share |
(3.04) | (2.79) | (2.52) | (2.30) | 2.09 | (2.01) | (1.33) | (0.71) | (3.48) | (3.38) |
Capex per Share |
0.00 | (0.01) | (0.05) | (0.01) | (0.01) | 0.00 | (0.01) | (0.04) | (0.09) | (0.48) |
Free Cash Flow per Share |
(3.04) | (2.80) | (2.57) | (2.31) | 2.08 | (2.02) | (1.34) | (0.76) | (3.58) | (3.87) |
Cash per Share |
5.71 | 8.77 | 11.65 | 15.00 | 13.09 | 7.43 | 9.42 | 10.81 | 11.09 | 11.26 |
Shareholders Equity per Share |
5.21 | 9.06 | 10.55 | 13.13 | 10.54 | 4.61 | 6.84 | 8.17 | 10.81 | 10.64 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.21 | 9.06 | 10.55 | 13.13 | 10.54 | 4.61 | 6.84 | 8.17 | 10.81 | 10.64 |
Free Cash Flow |
(163.72) | (150.35) | (136.68) | (109.28) | 92.03 | (80.56) | (53.52) | (30.00) | (134.70) | (132.89) |
Working Capital |
274.35 | 436.91 | 582.39 | 668.95 | 551.36 | 273.44 | 360.66 | 416.46 | 388.96 | 350.29 |
Capital Expenditures |
(0.14) | (0.30) | (2.77) | (0.46) | (0.57) | (0.20) | (0.55) | (1.73) | (3.52) | (16.64) |
Net Current Asset Value |
268.86 | 425.23 | 504.27 | 583.11 | 441.49 | 150.32 | 232.03 | 255.59 | 337.19 | 296.79 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 22.31 | 0.00 | 0.00 | 0.13 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.00 | 0.03 | 0.01 | 0.00 | 0.23 | 0.67 | 1.81 | 0.13 | 15.78 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 30.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.73 | 1.16 | 2.19 | 3.89 | 3.38 | 2.74 | 1.76 | 0.06 | 0.06 | 0.04 |
Cash ROIC |
(27.84%) | (15.69%) | (11.57%) | (8.20%) | 8.81% | (16.76%) | (8.25%) | (4.00%) | (16.33%) | (17.66%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 35.32 | 0.00 | 0.00 | 20.55 | 23.26 | 7.89 | 131.67 | 3.07 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — | — | — |
Average Receivables |
— | — | 2.59 | — | — | 0.04 | 0.04 | 0.12 | 0.21 | 0.34 |
Average Payables |
6.82 | 16.58 | 17.33 | 6.48 | 3.90 | 2.68 | 1.36 | 7.55 | 13.35 | 8.79 |
Average Assets |
436.96 | 621.75 | 727.21 | 683.70 | 471.17 | 376.12 | 459.03 | 497.56 | 478.15 | 422.61 |
Average Common Equity |
383.70 | 524.15 | 591.70 | 544.04 | 325.02 | 228.46 | 297.96 | 365.09 | 386.30 | 363.04 |
Columns are period end dates